Akcea Therapeutics, Inc. (NASDAQ:AKCA) recovered 117.04% of its value since hitting low of $8.10. The recent move of -8.53% drop pushed the stock to close at $17.58 when trading ended on 11/13/2017. At recent session, the prices were hovering between $17.0801 and $19.2401. This company shares are 36.52% off its target price of $24 and the current market capitalization stands at $1.11B. The recent change has given its price a -21.65% deficit over SMA 50 and -43.71% deficit over its 52-week high. The stock witnessed -23.7% declines, 24.42% gains and 0% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AKCA’s volatility during a week at 11.17% and during a month it has been found around 9.48%.Akcea Therapeutics, Inc. (AKCA) Top Holders
Institutional investors currently hold around $6 million or 13% in AKCA stock. Look at its top three institutional owners. Candriam Luxembourg S.C.A. owns $3.69 million in Akcea Therapeutics, Inc., which represents roughly 0.33% of the company’s market cap and approximately 61.52% of the institutional ownership. Similar statistics are true for the second largest owner, Bank Of New York Mellon Corp, which owns 51,068 shares of the stock are valued at $982 thousand. The third largest holder is New York State Common Retirement Fund, which currently holds $563 thousand worth of this stock and that ownership represents nearly 0.05% of its market capitalization.Akcea Therapeutics, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 14 institutional holders increased their position in Akcea Therapeutics, Inc. (NASDAQ:AKCA) by some 329,055 shares. That puts total institutional holdings at 329,055 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 329,055 shares.Akcea Therapeutics, Inc. (AKCA) Analyst Guide
Several analysts have released their opinion on Akcea Therapeutics, Inc. (NASDAQ:AKCA), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.